Raffit Hassan
National Institutes of Health
ImmunotoxinCancerInternal medicinePathologyOncologyAntigenMolecular biologyAntibodyImmunologyChemotherapyMesothelinPemetrexedMesotheliomaImmunotherapyPeritoneal mesotheliomaPleural mesotheliomaCancer researchMonoclonal antibodyMedicineBiology
197Publications
58H-index
8,624Citations
Publications 196
Newest
#1Jyoti Roy (NIH: National Institutes of Health)H-Index: 1
#2Elaine M. Jagoda (NIH: National Institutes of Health)H-Index: 28
Last. Frank I. Lin (NIH: National Institutes of Health)H-Index: 11
view all 13 authors...
Introduction: [227Th]Th-3,2-HOPO-MSLN-mAb, a mesothelin (MSLN)-targeted thorium-227 therapeutic conjugate, is currently in phase I clinical trial; however, direct PET imaging using this conjugate is technically challenging. Thus, using the same MSLN antibody, we synthesized 3,2-HOPO and deferoxamine (DFO)-based zirconium-89 antibody conjugates, [89Zr]Zr-3,2-HOPO-MSLN-mAb and [89Zr]Zr-DFO-MSLN-mAb, respectively, and compared them in vitro and in vivo. Methods: [89Zr]Zr-3,2-HOPO-MSLN-mAb and [89Zr...
Source
#1Zishuo I. HuH-Index: 1
#2Azam GhafoorH-Index: 4
Last. Raffit HassanH-Index: 58
view all 4 authors...
Malignant mesothelioma is an aggressive cancer with a poor prognosis and limited treatment options. For many years, the only US Food and Drug Administration-approved first-line treatment for unresectable mesothelioma was pemetrexed plus cisplatin. However, the recent approval of nivolumab plus ipilimumab as frontline treatment for patients with pleural mesothelioma marks a significant milestone for the treatment of this disease. In this review, the authors describe recent advances in therapeutic...
Source
#1Julie R. Brahmer (Johns Hopkins University)H-Index: 90
#2Melissa Lynne Johnson (Sarah Cannon Research Institute)H-Index: 29
Last. Raffit Hassan (NIH: National Institutes of Health)H-Index: 58
view all 19 authors...
Abstract Introduction JNJ-64041757 (JNJ-757) is a live, attenuated, double-deleted Listeria monocytogenes–based immunotherapy expressing human mesothelin. JNJ-757 was evaluated in patients with advanced NSCLC as monotherapy (phase 1) and in combination with nivolumab (phase 1b/2). Methods Patients with stage IIIB/IV NSCLC who had received previous therapy were treated with JNJ-757 (1 × 108 or 1 × 109 colony-forming units [CFUs]) alone (NCT02592967) or JNJ-757 (1 × 109 CFU) plus intravenous nivol...
Source
Last. Christine Alewine (LMB: Laboratory of Molecular Biology)H-Index: 10
view all 9 authors...
TPS452Background: LMB-100 recombinant immunotoxin consists of a mesothelin-binding Fab for targeting with a modified Pseudomonas exotoxin A payload. Formation of anti-drug antibodies (ADAs) is thou...
Source
#1Emily S. ReardonH-Index: 4
#2Vivek ShuklaH-Index: 15
Last. David S. SchrumpH-Index: 63
view all 23 authors...
Abstract Introduction Ubiquitin-like with plant homeodomain and ring finger domains 1 (UHRF1) encodes a master regulator of DNA methylation that has emerged as an epigenetic driver in human cancers. To date, no studies have evaluated UHRF1 expression in malignant pleural mesothelioma (MPM). This study was undertaken to explore the therapeutic potential of targeting UHRF1 in MPM. Methods Microarray, real-time quantitative reverse transcription–polymerase chain reaction, immunoblot, and immunohist...
3 CitationsSource
#1Angela Bononi (UH: University of Hawaii)H-Index: 26
#2Keisuke Goto (Hiroshima University)H-Index: 13
Last. Michele Carbone (UH: University of Hawaii)H-Index: 72
view all 27 authors...
Rare biallelic BLM gene mutations cause Bloom syndrome. Whether BLM heterozygous germline mutations (BLM+/−) cause human cancer remains unclear. We sequenced the germline DNA of 155 mesothelioma patients (33 familial and 122 sporadic). We found 2 deleterious germline BLM+/− mutations within 2 of 33 families with multiple cases of mesothelioma, one from Turkey (c.569_570del; p.R191Kfs*4) and one from the United States (c.968A>G; p.K323R). Some of the relatives who inherited these mutations develo...
2 CitationsSource
#1Raffit HassanH-Index: 58
#2Christine Alewine (LMB: Laboratory of Molecular Biology)H-Index: 10
Last. Ira Pastan (LMB: Laboratory of Molecular Biology)H-Index: 191
view all 18 authors...
Background LMB-100 is an antibody-toxin conjugate with an antimesothelin Fab linked to a 24-kilodalton portion of Pseudomonas exotoxin A with mutations that decrease immunogenicity. The objective of the current first-in-human phase 1 study was to determine the maximum tolerated dose (MTD) and safety in patients with advanced solid tumors expressing mesothelin. Methods Cohorts of 1 to 7 patients received intravenous LMB-100 at 7 dose levels from 40 µg/kg to 250 µg/kg intravenously on days 1, 3, a...
4 CitationsSource
#1James C. Reynolds (NIH: National Institutes of Health)H-Index: 71
#2Roberto Maass-Moreno (NIH: National Institutes of Health)H-Index: 7
Last. Raffit HassanH-Index: 58
view all 7 authors...
Cancer Survival is related to tumor volume. FDG PET measurement of tumor volume holds promise but is not yet a clinical tool. Measurements come in two forms: the total lesion volume (TLV) based on the number of voxels in the tumor and secondly the total lesion glycolysis (TLG) which is the TLV multiplied by the average SUL per voxel of the tumor (SUL is the standardize uptake value normalized for lean mass). In this study we measured tumor volume in patients with malignant pleural mesothelioma (...
1 CitationsSource
#1Raffit Hassan (NIH: National Institutes of Health)H-Index: 58
#2Markku Miettinen (NIH: National Institutes of Health)H-Index: 2
Last. Markku Miettinen (NIH: National Institutes of Health)H-Index: 115
view all 2 authors...
Source
#1Qun Jiang (NIH: National Institutes of Health)H-Index: 3
#2Azam Ghafoor (NIH: National Institutes of Health)H-Index: 4
Last. Raffit Hassan (NIH: National Institutes of Health)H-Index: 58
view all 13 authors...
LMB-100 is an immunotoxin targeting the cell surface protein mesothelin, which is highly expressed in many cancers including mesothelioma. Having observed that patients receiving pembrolizumab off protocol after LMB-100 treatment had increased tumor responses; we characterized these responses and developed animal models to study whether LMB-100 made tumors more responsive to antibodies blocking programmed cell death protein 1 (PD-1). The overall objective tumor response in the 10 patients who re...
5 CitationsSource